Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. Our first-in-class cell therapy product candidates undergoing clinical development today utilize healthy donor cells, which we modify ex vivo using pharmacologic modulators, such as small molecules, to improve the cells’ biological properties and therapeutic function. We are also pioneering a revolutionary approach to cell therapy – we use renewable master induced pluripotent stem cell (iPSC) lines generated from our proprietary iPSC platform to derive cell therapy product candidates that can be delivered off-the-shelf for the treatment of a large number of patients.